Shifting the AKI paradigm

Shifting the AKI paradigm

Shifting the AKI paradigm

From diagnosis to prevention

Acute kidney injury (AKI) presents an increasing burden worldwide. When not detected at an early stage, AKI can lead to poor patient outcomes and increased healthcare expenditures. Now your clinicians can rapidly assess critically ill patients for risk of moderate to severe AKI.

Sales Support

Phone:43 68 20 01 [DK]
08 629 00 81/89 [SE]
21 09 75 55 [NO]

Fax:43 31 45 22 [DE]
08 578 770 58 [SE]
21 09 76 66 [NO]

Request sales information  

Getting ahead of AKI:
Identify the risk of kidney injury before damage occurs

Two biomarkers. One test.
The Ortho Solution: Minimal investment for rapid impact

The NEPHROCHECK® Test is the first commercially available urine test that:

  • Measures two biomarkers thought to be involved in G1 cell-cycle arrest during the earliest phases of Kidney stress4
  • Detects kidney stress through elevated TIMP-2 and IGFBP-7 levels before AKI becomes apparent through traditional functional tests such as urine output and serum creatinine.4,5
  • Was discovered and validated as an AKI risk assessment tool for the development of moderate to severe AKI in two large international clinical trials across 29 sites with a combined 1200+ patients.5



The Ortho Solution: Minimal investment for rapid impact

The NEPHROCHECK® Test is available now either built-in our VITROS® automated systems or as a standalone meter to provide clinical laboratories and clinician’s confident results.

  • The ONLY risk assessment test for AKI
  • A simple urine test providing results in about 20 minutes
  • Peer-reviewed evidence
  • Easy and cost-effective to implement
  • Allows clinicians to intervene proactively





Acute Kidney Injury and the role of cell-cycle arrest biomarkers



Press Releases









1. Premier, Inc. Complications Research: Identifying hospital-wide harm associated with increased cost, length of stay and mortality in U.S. hospitals. Available at: http:// Accessed 1 December 2015
2. Findings from a meta-analysis of 765 studies representing >77 million patients - Mehta RL, et al. Lancet. 2015;385:2616-2643.
3. Findings from a study of 14,524 ICU patients Mandelbaum T, et al. Crit Care Med. 2011;39:2659- 2664.
4. Kellum JA, et al. Nephrol Dial Transplant. 2016; 31(1):16-22
5. Kashani K, et al. Crit Care. 2013;17(1):R25.

All trademarks are the property of Ortho Clinical Diagnostics, Inc. except the NephroCheck® and AKIRISK® which are registered trademarks of Astute Medical, Inc. in the United States.
VITROS® NEPHROCHECK® is not available in the USA. Product availability is subject to fulfillment of regulatory requirements in each market.
© Ortho Clinical Diagnostics 2019. Ortho Clinical Diagnostics, publishes this site and is solely responsible for its content. The availability of the products is subject to compliance with the regulatory requirements of each market.